ArticleCurrent medical science2026
NCOA1 Attenuates High Glucose-Induced Mesangial Matrix Expansion Through ITGA5 Inhibition.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo investigate whether nuclear receptor coactivator 1 (NCOA1) participates in the pathogenesis of diabetic kidney disease (DKD) by modulating extracellular matrix (ECM) production in mesangial cells (MCs), and to explore the underlying molecular mechanism.
methodsThe rat glomerular MCs and streptozotocin-induced DKD mouse models were employed. NCOA1 expression was evaluated under both normal and high-glucose conditions. The functional role of NCOA1 was assessed via plasmid-mediated overexpression in high-glucose treated MCs. Integrin alpha 5 (ITGA5) expression was examined in vivo and in vitro, and its regulatory relationship with NCOA1 was investigated. Furthermore, siRNA-mediated knockdown of ITGA5 was performed to determine its necessity in high-glucose driven ECM overproduction.
resultsNCOA1 was abundantly expressed in resting MCs but markedly downregulated upon high-glucose stimulation. Plasmid-driven overexpression of NCOA1 significantly attenuated high-glucose induced ECM protein synthesis. Notably, ITGA5 expression was substantially elevated in the glomerular mesangium of DKD mice and in high-glucose exposed MCs, and this upregulation was negatively governed by NCOA1. Functionally, ITGA5 silencing effectively abrogated the excessive matrix production provoked by high glucose, phenocopying the protective effect of NCOA1 overexpression.
conclusionNCOA1 protects against high-glucose induced mesangial expansion in DKD, at least partially, through negative regulation of ITGA5. These findings identify the NCOA1/ITGA5 axis as a potential therapeutic target for counteracting glomerular fibrosis in DKD.
Indexed as
Identifiers
42671772What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.